Previous Close | 4.3000 |
Open | 4.2800 |
Bid | 4.2400 x 2200 |
Ask | 4.2500 x 3200 |
Day's Range | 4.2200 - 4.3400 |
52 Week Range | 3.3200 - 7.8000 |
Volume | |
Avg. Volume | 3,021,618 |
Market Cap | 566.895M |
Beta (5Y Monthly) | 0.92 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8000 |
Earnings Date | May 10, 2023 - May 15, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.23 |
Subscribe to Yahoo Finance Plus to view Fair Value for CTIC
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive P
CTI BioPharma Corp. (NASDAQ:CTIC) Q4 2022 Earnings Call Transcript March 6, 2023 Operator: Good morning, and welcome to the CTI BioPharma Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded. I would now like to introduce your host, Remy Bernarda, CTI Investor Relations. […]